- Home
- PNFP vs LEGN Comparison
PNFP vs LEGN Comparison
Compare PNFP & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNFP
- LEGN
- Stock Information
- Founded
- PNFP 2000
- LEGN 2014
- Country
- PNFP United States
- LEGN United States
- Employees
- PNFP N/A
- LEGN N/A
- Industry
- PNFP Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- PNFP Finance
- LEGN Health Care
- Exchange
- PNFP Nasdaq
- LEGN Nasdaq
- Market Cap
- PNFP 7.0B
- LEGN 6.3B
- IPO Year
- PNFP N/A
- LEGN 2020
- Fundamental
- Price
- PNFP $91.88
- LEGN $33.23
- Analyst Decision
- PNFP Buy
- LEGN Buy
- Analyst Count
- PNFP 13
- LEGN 11
- Target Price
- PNFP $115.62
- LEGN $71.90
- AVG Volume (30 Days)
- PNFP 1.1M
- LEGN 1.4M
- Earning Date
- PNFP 10-15-2025
- LEGN 11-11-2025
- Dividend Yield
- PNFP 1.04%
- LEGN N/A
- EPS Growth
- PNFP 48.26
- LEGN N/A
- EPS
- PNFP 7.51
- LEGN N/A
- Revenue
- PNFP $1,812,787,000.00
- LEGN $796,838,000.00
- Revenue This Year
- PNFP $29.32
- LEGN $70.27
- Revenue Next Year
- PNFP $12.15
- LEGN $50.28
- P/E Ratio
- PNFP $12.28
- LEGN N/A
- Revenue Growth
- PNFP 21.56
- LEGN 74.75
- 52 Week Low
- PNFP $81.57
- LEGN $27.34
- 52 Week High
- PNFP $131.91
- LEGN $51.77
- Technical
- Relative Strength Index (RSI)
- PNFP 45.48
- LEGN 48.78
- Support Level
- PNFP $86.85
- LEGN $30.77
- Resistance Level
- PNFP $95.49
- LEGN $33.21
- Average True Range (ATR)
- PNFP 2.46
- LEGN 1.35
- MACD
- PNFP -0.37
- LEGN 0.19
- Stochastic Oscillator
- PNFP 52.12
- LEGN 68.52
About PNFP Pinnacle Financial Partners Inc.
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.